Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $2M | $-178M | $-162M | $-129M | -32.9% | -67.3% | 91.1% |
| 2024 | $6M | $-101M | $-85M | $-78M | -24.1% | 120.6% | 95.1% |
| 2023 | $3M | $-48M | $-44M | $-37M | -25.8% | -56.0% | 53.0% |
| 2022 | $6M | $-30M | $-28M | $-29M | 64.2% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 2.04 |
| Operating Revenue | 2.04 |
| Operating Expense | 179.97 |
| Research And Development | 145.64 |
| Selling General And Administration | 34.33 |
| Total Expenses | 179.97 |
| Operating Income | -177.93 |
| Total Operating Income As Reported | -177.93 |
| EBITDA | -177.50 |
| Normalized EBITDA | -177.96 |
| EBIT | -177.93 |
| Interest Income | 16.12 |
| Net Interest Income | 16.12 |
| Other Non Operating Income Expenses | -0.97 |
| Other Income Expense | -0.52 |
| Interest Income Non Operating | 16.12 |
| Net Non Operating Interest Income Expense | 16.12 |
| Pretax Income | -162.34 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 0 |
| Net Income Continuous Operations | -162.34 |
| Net Income From Continuing And Discontinued Operation | -162.34 |
| Net Income From Continuing Operation Net Minority Interest | -162.34 |
| Net Income | -162.34 |
| Net Income Common Stockholders | -162.34 |
| Net Income Including Noncontrolling Interests | -162.34 |
| Normalized Income | -162.79 |
| Diluted NI Availto Com Stockholders | -162.34 |
| Basic Average Shares | - |
| Diluted Average Shares | - |
| Reconciled Depreciation | 0.43 |
| Total Unusual Items | 0.45 |
| Total Unusual Items Excluding Goodwill | 0.45 |
| Gain On Sale Of Security | 0.45 |
| General And Administrative Expense | 34.33 |
| Other Gand A | 34.33 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Dianthus Therapeutics, Inc.this co. | DNTH | $4.6B | -28.33 | 9.32 | -32.9% | -25.63 |
| Xenon Pharmaceuticals Inc. | XENE | $5.1B | -14.81 | 8.80 | -59.5% | -13.31 |
| CG Oncology, Inc. | CGON | $4.9B | -30.73 | 6.57 | -21.4% | -26.00 |
| Twist Bioscience Corporation | TWST | $4.6B | -59.27 | 9.73 | -16.4% | -40.36 |
| Amicus Therapeutics, Inc. | FOLD |
| - |
| - |
| - |
| - |
| - |
| - |
| $4.5B |
| -167.83 |
| 16.59 |
| -9.9% |
| 88.80 |
| Celcuity Inc. | CELC | $4.5B | -25.47 | 44.85 | -176.1% | -29.21 |
| Travere Therapeutics, Inc. | TVTX | $4.3B | -168.11 | 37.40 | -22.2% | 203.89 |
| 10x Genomics, Inc. | TXG | $4.3B | -97.67 | 5.34 | -5.5% | 988.34 |
| Erasca, Inc. | ERAS | $4.1B | -33.13 | 12.69 | -38.3% | -31.96 |
| Peer Median | - | -46.20 | 11.21 | -21.8% | -19.65 | |